The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000493347
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
6/04/2026
Date registered
Help: Date registered
21/04/2026
Date last updated
Help: Date last updated
21/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
21/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Efficacy of Prucalopride to Treat Systemic Sclerosis Gastrointestinal Disease
Scientific title
n-of-1 Trial of the Efficacy of Prucalopride to Treat Systemic Sclerosis Associated Gastrointestinal Dysmotility
Additional trial identifiers [1] 316954 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Systemic sclerosis 341397 0
Gastrointestinal dysmotility 341398 0
Condition category
Condition code
Inflammatory and Immune System 337463 337463 0 0
Connective tissue diseases
Oral and Gastrointestinal 337464 337464 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Intervention;
Prucalopride
2mg, administered orally, once daily for 6 weeks

Participants will cycle through four treatment cycles, alternating between prucalopride and placebo. Participants and study investigators will be blinded to treatment assignment in each treatment cycle. Treatment cycles will be 6 weeks in length. There will be a one week washout period between treatment cycles, during which participants will take no medication or placebo tablets.

All participants will receive 2mg of prucalopride / 2mg placebo in each treatment cycle, with burden of gastrointestinal symptoms assessed at the end of each treatment cycle. Treatment adherence will be assessed at the end of every 2nd treatment cycle, by study investigators, by counting number of tablets remaining at the end of the treatment cycles.

The study will take place at an urban tertiary hospital.
Intervention code [1] 333682 0
Treatment: Drugs
Description of the comparator or control
Each participant will undertake two cycles of treatment and two cycles of placebo therapy, in a random order, during the study. Both participants and investigators will be blinded to ordering of treatment cycles.

Each participant will act as their own control participant. Gastrointestinal symptom control will be compared within each participant between cycles of treatment and cycles of placebo.

Placebo treatment will be administered as a microcrystalline cellulose capsule.
Control group
Placebo

Outcomes
Primary outcome [1] 344973 0
Change in gastrointestinal symptoms.
Timepoint [1] 344973 0
Symptom assessment at conclusion of each treatment cycle (6 weekly for up to 27 weeks following randomisation).
Secondary outcome [1] 459985 0
Whole gut transit time
Timepoint [1] 459985 0
Week 27 post first-treatment dose.
Secondary outcome [2] 459986 0
Faecal microbiome composition
Timepoint [2] 459986 0
Week 27 post first-treatment dose.

Eligibility
Key inclusion criteria
Confirmed diagnosis of systemic sclerosis as per 2013 ACR/EULAR classification criteria
Age between 18 and 80 years
At least one regular symptom of gastrointestinal dysmotility, e.g. difficulty swallowing, nausea, early satiety, vomiting, abdominal bloating or discomfort, diarrhoea, constipation
Confirmed gastrointestinal dysmotility by whole gut transit study
Minimum age
18 Years
Maximum age
80 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Current use of prokinetic medication (e.g. metoclopramide, domperidone, erythromycin, prucalopride, octreotide, anticholinesterase inhibitor)
• Current antibiotic treatment for small intestinal bacterial overgrowth (Patients are ineligible for this study if they have used any antibiotics in the 4 weeks prior to baseline study visit. Meaning patients who are on long term or cyclical antibiotics for management of SIBO will be ineligible for inclusion in this study.)
• Current use of GLP-1 receptor agonist
• Current use of opiate analgesia
• Requirement for enteral or parenteral feeding
• Pregnant and or breast-feeding
• Individuals not fluent in English or unable to read English.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Block randomisation, with 6 participants per block.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 3
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321551 0
Charities/Societies/Foundations
Name [1] 321551 0
Arthritis Australia
Country [1] 321551 0
Australia
Primary sponsor type
Hospital
Name
St Vincent's Hospital Melbourne
Address
Country
Australia
Secondary sponsor category [1] 324333 0
None
Name [1] 324333 0
Address [1] 324333 0
Country [1] 324333 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 320084 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 320084 0
Ethics committee country [1] 320084 0
Australia
Date submitted for ethics approval [1] 320084 0
Approval date [1] 320084 0
05/12/2025
Ethics approval number [1] 320084 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149378 0
Dr Laura Ross
Address 149378 0
St Vincent's Hospital 41 Victoria Pde Fitzroy VIC 3065
Country 149378 0
Australia
Phone 149378 0
+61 3 9231 2211
Fax 149378 0
Email 149378 0
Contact person for public queries
Name 149379 0
Ms Elizabeth Reidy
Address 149379 0
St VIncent's Hospital Melbourne 41 Victoria Pde Fitzroy VIC 3065
Country 149379 0
Australia
Phone 149379 0
+61 3 9231 3983
Fax 149379 0
Email 149379 0
Contact person for scientific queries
Name 149380 0
Laura Ross
Address 149380 0
St Vincent's Hospital 41 Victoria Pde Fitzroy VIC 3065
Country 149380 0
Australia
Phone 149380 0
+61 3 9231 2211
Fax 149380 0
Email 149380 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.